Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks to Buy for Steady Income.

On March 19, Barclays raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $234 from $217. It kept an Equal Weight rating on the shares. The firm said its analysis confirms the company’s “strong” 23% US pharma growth excluding Stelara in Q4 is carrying into Q1. Growth is coming from both established products and newer franchises in the US. Barclays increased its estimates following that trend.

On March 12, the company announced U.S. Food and Drug Administration approval of TECNIS PureSee IOL, an extended depth of focus intraocular lens designed for cataract surgery. The company said the lens delivers clear vision, with 97% of patients reporting no very bothersome visual disturbances. TECNIS PureSee IOL is expected to become available in the U.S. later this year.

The product adds to Johnson & Johnson’s surgical vision portfolio, which builds on 25 years of intraocular lens innovation. Each year, millions of patients globally receive TECNIS lenses as part of cataract procedures.

Johnson & Johnson (NYSE:JNJ) operates across a wide range of healthcare products through two segments: Innovative Medicine and MedTech.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading into 2026 and 14 Under-the-Radar High Dividend Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.